Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,470.00    50.00 (2.07%)
Bid:
2,466.00
Ask:
2,470.00
Spread: 4.00 (0.162%)
Market Cap: £7.93b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

14 Oct 2020 07:00

RNS Number : 9693B
Bunzl PLC
14 October 2020
 

14 October 2020

 

BUNZL Q3 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2020.

 

Bunzl's diversified and resilient business model has delivered strong overall growth over a challenging period, with Group revenue for the third quarter up 4.0% at actual exchange rates and 8.8% at constant exchange rates. Underlying revenue increased strongly by 8.0% at constant exchange rates reflecting the continued growth in the sale of Covid-19 related products, such as masks, sanitisers, gloves and disinfectants. Of the total growth at constant exchange rates, acquisitions contributed 4.0%, including the impact of MCR Safety which was completed at the beginning of September. The third quarter had fewer trading days than the comparable period in 2019 which reduced revenue growth at constant exchange rates by 3.2%.

 

Within the underlying revenue growth of 8.0%, sales of the top 8 Covid-19 related products, which are primarily own brand, contributed 17.5% of growth. This growth more than offset a 9.5% decline in revenue from other product sales. Larger orders of the top 8 Covid-19 related products, although lower than in the second quarter, were in line with expectations, with smaller orders also lower but remaining strong. The 9.5% decline in revenue from other product sales was less than the second quarter reflecting the easing of pandemic-related restrictions across the Company's markets.

 

The 2020 performance year to date has been driven by strong sales of Covid-19 related products, from a combination of smaller orders and the more exceptional larger orders. This has more than offset the impact of weak economic activity on the Group's business. Looking forward, the outlook remains uncertain, particularly considering current pandemic trends and the increasing restrictions which are now being reintroduced in some markets that may limit the continued underlying recovery. In addition, larger Covid-19 related orders are expected to be more limited. However, given the performance year to date and the impact of recently announced acquisitions, the Company currently expects revenue in the second half of 2020 to grow strongly at constant exchange rates and anticipates a slightly higher second half operating profit margin compared to the prior year.

 

Further to the announcement issued on 24 August 2020, the Company has recently completed the acquisition of Abco Kovex, a distributor of flexible packaging based in Ireland with revenue of €23 million. Growth through acquisitions continues to be an important part of the strategy of the Group and the acquisition pipeline remains promising with a number of discussions ongoing.

 

This announcement contains inside information.

 

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

Conference call:

 

There will be a live analyst and investor conference call and Q&A session from 08:00am (BST) today. To join the conference call refer to the dial-in details below (please allow time for registration).

 

· Dial-in number: +44 33 0606 1122

· Room number: 710652

 

The conference call replay will be available on demand later in the day via Bunzl's Investors section on the corporate website (https://www.bunzl.com/investors/presentations.aspx).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUBDGLXBDGGX
Date   Source Headline
1st Apr 202211:13 amRNSTotal Voting Rights
17th Mar 20224:15 pmRNSAnnual Financial Report
15th Mar 202211:30 amRNSDirector Declaration
3rd Mar 20225:07 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:12 pmRNSDirector/PDMR Shareholding
2nd Mar 20225:36 pmRNSDirector/PDMR Shareholding
1st Mar 20225:58 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20229:00 amRNSDirector Declaration
28th Feb 20227:00 amRNSAnnual Financial Report
3rd Feb 20224:06 pmRNSDirector/PDMR Shareholding
2nd Feb 20225:30 pmRNSDirectorate Change
1st Feb 202210:58 amRNSTotal Voting Rights
12th Jan 202212:15 pmRNSDirector/PDMR Shareholding
12th Jan 20227:00 amRNSAcquisition
10th Jan 20225:34 pmRNSDirector/PDMR Shareholding
7th Jan 202211:54 amRNSDirector/PDMR Shareholding
4th Jan 20225:56 pmRNSTotal Voting Rights
15th Dec 20217:00 amRNSTrading Statement
10th Dec 20213:18 pmRNSDirector/PDMR Shareholding
8th Dec 20214:30 pmRNSDirector Declaration
8th Dec 20218:00 amRNSAdditional Listing
3rd Dec 20214:27 pmRNSDirector/PDMR Shareholding
1st Dec 20214:50 pmRNSDirector/PDMR Shareholding
1st Dec 202110:20 amRNSTotal Voting Rights
18th Nov 20217:00 amRNSAcquisition
10th Nov 20213:00 pmRNSPublication of Admission Particulars
4th Nov 20215:41 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
1st Nov 20213:14 pmRNSTotal Voting Rights
1st Nov 20219:00 amRNSBlock listing Interim Review
29th Oct 20211:10 pmRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSTrading Statement
19th Oct 20215:12 pmRNSDirector/PDMR Shareholding
19th Oct 20215:11 pmRNSDirector/PDMR Shareholding
11th Oct 20217:00 amRNSCapital Markets Day
8th Oct 20212:28 pmRNSDirector/PDMR Shareholding
8th Oct 20212:24 pmRNSDirector/PDMR Shareholding
5th Oct 202110:16 amRNSDirector/PDMR Shareholding
1st Oct 202112:36 pmRNSTotal Voting Rights
14th Sep 20217:00 amRNSAcquisition
3rd Sep 202112:30 pmRNSDirector/PDMR Shareholding
1st Sep 20214:00 pmRNSTotal Voting Rights
31st Aug 20214:30 pmRNSDividend Declaration
31st Aug 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSAcquisition
4th Aug 202111:24 amRNSDirector/PDMR Shareholding
2nd Aug 20213:40 pmRNSTotal Voting Rights
14th Jul 20214:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.